Statistics of monocyte analysis from SLE patients and healthy controls
| Analysis | SLE | Donor | p of SLE versus donor | |
| PBM (day 0) | (n=17) (10/7) | (n=8) | ||
| CD14 | 37.4% | 90.4 % | <0.0001 | |
| range: 12–85.4% | range: 79.2–97% | |||
| MFI 94 | MFI 258 | 0.002 | ||
| HLA-DR | 28.9% | 71.5% | 0.0003 | |
| range: 5.2–47% | range: 20.3–91.3% | |||
| CD71 | 5/17 | 0/8 | ||
| MoAC (day 3) | (n=12) (7/5) | (n=6) | ||
| CD1 | 12.4% | 49.6% | 0.008 | |
| range: 0–37.8 | range: 21–88.9 | |||
| CD14 | 85.2% | 43.1% | 0.001 | |
| range: 60.8–98 | range: 6.5–74 | |||
| HLA-DR | MFI 39 | MFI 90 | 0.022 | |
| MoDC (day 3) | (n=6) (3/3) | (n=6) | ||
| CD1 | 21.8% | 75.4% | 0.0007 | |
| range: 16.1–35.2% | range: 65.2–96.5% | |||
| CD14 | 90.6% | 57.8% | 0.0007 | |
| range: 79.2–99.8% | range: 44.3–71% | |||
| MFI 150 | MFI 43 | 0.0027 | ||
| HLA-DR | 79.2% | 91.2% | 0.059 | |
| range: 61.4–96.6% | range: 83.3–99.8% | |||
| MFI 317 | MFI 524 | 0.081 | ||
| TNFα (24 h) | (n=23) | (n=6) | ||
| MoAC (n=17) (10/7) | 4306 pg | 366 pg | 0.0004 | |
| range: 289–12 300 | range: 50–1202 | |||
| MoDC (n=6) (3/3) | 1965 pg | 0.0150 | ||
| range: 902–2566 | ||||
Groups are listed according to the experimental setting (analysis). Data shown represent the relevant results where monocytic cells of SLE patients differ from monocytic cells of healthy donors. With the exception of HLA-DR on MoDC of SLE patients all differences listed are statistically significant (p<0.05). The number of active/inactive patients is given in parentheses. PBM, peripheral blood monocytes; MoAC, monocyte derived accessory cells (non-supplemented), TNFα, tumour necrosis factor α; MoDC, monocyte derived dendritic cells (GM-CSF and IL4 supplemented); MFI, mean fluorescence intensity.